Opioid use disorder - Articles - Page 5

Clinical Guidance

Opioids: The Basics of Street Drugs

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

The global supply of illicit opioids is rapidly shifting and unstable.

Fact Sheet

Teaching Relapse Prevention Techniques in Alcohol Use Disorder

January 1, 2025

Michael Weaver, MD, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Weaver, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Most patients are not able to achieve sobriety from opioids in their first attempt.

Fact Sheet

Sample ABCD Worksheet for Cognitive Behavioral Therapy

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Puzantian, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

ABCD worksheet for Opioid Use Disorder.

Fact Sheet

Opioid Use Disorder: Psychosocial Approaches

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Hendrick and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Research shows that effective opioid use disorder (OUD) treatment must include a medication such as buprenorphine, methadone, or injectable naltrexone as its main component.

Fact Sheet

Motivational Interviewing in Opioid Use Disorder

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Hendrick and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Motivational interviewing (MI) is a therapeutic approach that focuses on a patient’s own motivation and commitment to change.

Fact Sheet

Contingency Management for Opioid Use Disorder

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Hendrick and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Contingency management (CM) is a strategy based on rewarding positive behaviors to encourage change.

Fact Sheet

12-Step Programs and Opioid Use Disorder

January 1, 2025

Noah Capurso, MD, MHS, Talia Puzantian, PharmD, BCPP, and Daniel Carlat, MD

Dr. Capurso, Dr. Hendrick, and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

12-step peer support groups such as Alcoholics Anonymous (AA) or Narcotics Anonymous (NA) are associated with better outcomes for those already taking medication for opioid use disorder (MOUD)

Research Update

Long-Term Patient Outcomes with Buprenorphine for Opioid Use Disorder

January 1, 2025

Peter J. Farago, MD.

Peter Farago, MD. Dr. Farago has no financial relationships with companies related to this material.

Researchers compare outcomes in patients who take buprenorphine for shorter and for longer. Their findings are revealing.

Clinical Update

Effective Management of Buprenorphine-Precipitated Opioid Withdrawal

January 1, 2025

Jaewon Lee, MD, MPH

Jaewon Lee, MD, MPH. PGY-2, psychiatry resident, University of Rochester Medical Center, Rochester, NY.

Dr. Lee has no financial relationships with companies related to this material.

Buprenorphine is a first-line treatment for opioid use disorder, however, given buprenorphine to a patient who still has opioids in their system can precipitate severe withdrawal. Careful assessment of withdrawal can minimize the risk, but despite our best efforts, precipitated withdrawal can still occur. In this article, we review what to do for our patients experiencing buprenorphine-precipitated opioid withdrawal.

Research Update

Rapid Initiation of Extended-Release Buprenorphine

October 1, 2024

Aniruddha Deka, MD

Aniruddha Deka, MD. Dr. Deka has no financial relationships with companies related to this material.

Long-acting buprenorphine is a promising new treatment for opioid use disorder, but it usually requires a seven-day stabilization period before initiation. Here, researchers develop and evaluate a novel protocol for initiating long-acting injectable buprenorphine in a single day. The trial is small, but results are promising.